By Mike Stobbe

A month after federal officials recommended new versions of COVID-19 vaccines, 7% of U.S. adults and 2% of children have gotten a shot.

One expert called the rates “abysmal.”

The numbers, presented Thursday at a meeting held by the Centers for Disease Control and Prevention, come from a national survey of thousands of Americans, conducted two weeks ago.

The data also indicated that nearly 40% of adults said they probably or definitely will not get the shot. A similar percentage of parents said they did not plan to vaccinate their children.

In the late summer, government health officials made the nation's COVID-19 vaccination campaign more like the annual flu campaign.

Officials approved updated shots that have a single target, an omicron descendant named XBB.1.5. They replaced vaccines that targeted the original coronavirus strain and a much earlier omicron version. Last month, the CDC recommended the new shots for everyone 6 months and older.

The government also transitioned to a commercialized system that relied on the health-care industry — not the government — to handle the distribution of the shots. Many people who immediately went for shots said pharmacies or doctors didn't have them.

Americans have been urged to get different iterations of the vaccines for more than 2/12 years. This year, COVID-19 deaths and hospitalizations fell to lower levels than seen in the previous three years.

Cases remain low compared with the pandemic's early months. Even so, health officials say about 18,000 hospitalization and 1,200 deaths are still being reported each week.

One expert at the meeting, Dr. Camille Kotton of Harvard Medical School, called the numbers “abysmal” and said part of the problem may be patient confusion. She urged stepped-up public education efforts.

Dr. David Kimberlin, of the University of Alabama at Birmingham, also expressed dismay.

“The recommendations are not being heard," he said.

Share:
More In Science
One Good Thing: All 14 Patients in Experimental Trial Saw Cancer Go Into Remission
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
A New Plant-Based Way to Quit Smoking
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
Plant-Based Way to Quit Smoking; Innovation in Stroke Therapy
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Load More